Fapon Biotech Inc. of Dongguan at MEDICA 2021 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option
Premium Exhibitor Manufacturers Service OEM

Fapon Biotech Inc.

No. 5 Hualian Road, Taiwan High-Tech Industrial Park, Songshan Lake, 523808 Dongguan

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Media files

Hall map

MEDICA 2021 hall map (Hall 3): stand A81

Fairground map

MEDICA 2021 fairground map: Hall 3



Please log in

You must be logged in to use matchmaking

Please log in for matchmaking

Registration is required to use the networking service and a separate registration for matchmaking. Please register for Matchmaking first.

Let's get started!

Welcome to Matchmaking. Would you like to get in touch with ?

Our range of products

Product categories

  • 03  Diagnostic tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.01  Immuno assay testing

Our products

Product category: Immuno assay testing

Shine i2000 Fully Automatic CLIA Analyzer

Excellent Performance
  • Up to 200 T/H, First result in ≤ 15 min
  • Batch CV ≤ 3%
Compact & Convenient
  • Volume of 0.51m³, patented technology for highly integrated and simplified design
  • Batch/random/STAT mode available
  • Integrated control panel with machine, all consumable loading in real time
Innovative Design
  • Incubation, washing and detection all-in-one, detection efficiency improved
  • Using automatic intelligent control technology, low instrument failure rate
  • 100+ patented technologies, 100% self-developed
Compatible system
  • Compatible with AE/AP/HRP/ABEI CLIA assay protocol
  • Compatible with immunological reagents and instruments with different parameters and reaction modes

More Less

Company news



21 Jun 2021

The Pressing Need for Early Detection of Mucormycosis during COVID-19

Mucormycosis or black fungus, a devastating infection that soars in India during COVID-19 has seized global attention. Recently, the country's mucormycosis cases reached over 57,150 and resulted in 54% mortality. Apart from the association with high diabetes prevalence in India, COVID-19 infected countries (Pakistan, Russia, Nepal, Chile, Brazil, etc.) have also described the same issue, areas with high diabetes and COVID-19 infection rates should be alarmed.

Unfortunately, mucormycosis is always being diagnosed late with prolonged COVID-19 healthcare burdens that deteriorate the situation. As a company making continuous research and contribution to the world's major infectious diseases with the mission to Enable Disease Identification Earlier, More Accurate, Convenient and Affordable, Fapon Biotech Inc. (Fapon Biotech) calls for cooperation with academic and industry partners in developing mucormycosis diagnostic tests to ease the challenge by sharing the abilities of upstream raw material development platforms and downstream reagent application platforms.

Fapon Biotech is one of the mainstream COVID-19 reagent raw material suppliers with proven experiences helping partners to launch accredited COVID-19 reagents in a short time. The company has over 1000 IVD partners worldwide with more than 10 years of business operation in India. Its technology platforms can match the R&D process from partners easily and provide supports from biomarker discovery to commercialization. Through different application platforms of Fapon Biotech (Colloidal Gold/Immunofluorescence/ELISA/CLIA/Latex-Enhanced Immunoturbidimetry/PCR/etc.), biomarkers can quickly complete the process of application development. For partners encountering production challenges, OEM and contract manufacturing services with the capacity reaching hundreds of grams of each batch are available. Because of a strong relationship with laboratories and IVD manufacturers in India, cooperating with Fapon Biotech will have the access to more resources and commercial opportunities, such as clinical samples for research and product validation, technology iterations, product launch and promotion, etc.

As the virus continues its mutation and triggers diseases like mucormycosis to complicate the situation, rapid responses via global cooperation will be crucial for areas with overwhelmed healthcare burdens. Fapon Biotech is committed to fueling the advancement of COVID-19 diagnosis through collaborations with international IVD partners.

More Less

19 Feb 2021

Fapon Biotech Introduces POCT Solution for COVID-19 E484K Mutation Testing

Fapon Biotech makes persist efforts to deal with the global pandemic new challenge, introduces COVID-19 Variant E484K POCT Solution for the effective differentiation of E484K and non-E484K infection. Previously, the company took a significant innovative step for being the first in the world in launching POCT Solution for variant B.1.1.7 (VUI 202012/01) and wild-type virus differentiation (https://bit.ly/3qDsmky). These solutions using POCT mechanism to offer additional values to the variant diagnosis using genome sequencing and PCR technologies, being an excellent mean to fight against the global-spread of mutant viruses.

New challenges in E484K and other mutant strains identification

The 'escape mutation' E484K that firstly found in 501Y.V2 (B.1.351) and 501Y.V3 (B.1.1.28) variant strains in the South African and Brazilian has now spread to UK, Mayotte, Belgium, France, Switzerland and other countries according to GISAID.

E484K is named 'an escape mutation' because it helps the virus bypass the body's immune defences and weakens the protective effect of some vaccines. In February, South Africa halt its rollout of the Oxford-AstraZeneca vaccine after a study showed "disappointing" results against the new variant. A study from Cambridge University has even confirmed the combination of more transmissible variant B.1.1.7 and E484K mutation substantially increases the amount of serum antibody needed to prevent infection of cells.

Moreover, the Manaus city in Brazil that thought to reach herd immunity in the first wave are now experiencing a second outbreak, and the situation is fuelling by the COVID-19 variants. However, only 0.03% of cases in Brazil underwent genomic sequencing for variant identification due to the lacking of resources.

The fight of COVID-19 is facing new challenges caused by complex variants and mutation. As a mainstream COVID-19 raw material supplier to the global top-profile reagent manufacturers, Fapon Biotech continues to keep a close watch on the ever-changing pandemic situation and introduce products for other mainstream strain identification.

More Less

10 Aug 2020

Fapon 2nd COVID-19 Donation, 100 Million Anti-SARS-CoV-2 Fully Human RBD IgM & IgG QC Test Materials

Fapon Biotech Inc. (Fapon), a global leading IVD raw materials and one-stop solutions company, announces a new COVID-19 donation to meet the urgent demand for development and optimization of reliable quality controls for high-quality antibody tests by donating 100 million Anti-SARS-CoV-2 Fully Human RBD IgM & IgG QC test materials. The first donation initiated in February to provide 3 million PCR test components to solve the shortage of raw materials. The new charitable action will reinforce Fapon's corporate mission to Enable Earlier Disease Identification; More Convenient, Accurate and Affordable Diagnosis upon the fight of COVID-19.

The daily production of COVID-19 antibody tests is massive, as it is not only applied to assess infection but also other medical fields. However, news of false-negative test results has never stopped. Fapon RBD IgM & IgG QC materials can aid the development and optimization of reliable quality controls, ultimately improve antibody test performance and tackle the false-negative challenge.

"In this unprecedented time with continually changing medical needs, we are utterly resolute in bringing tangible, beneficial impacts on the industry by supporting partners with what they need now and next," stated by the CEO of Fapon.

"The industry's feedback on our first PCR donation was extraordinary. We alleviated the raw material shortage. PCR manufacturers over forty countries collaborated with us to develop and manufacture tests. We had supplied raw materials for the manufacturing of over 100 million diagnostic tests and ramped up the production capacity of 500%."

"This second donation offers high-demand QC materials that sit in the heart of reliable antibody tests. It will help to accelerate the internal QC process and achieve test result confidence. We strongly look forward to the participation of global IVD partners."

Fapon manifests unmatched R&D capabilities during the pandemic to bring new COVID-19 products continuously to the market. Featured products include N Antibodies, N/S/RBD Antigens, ACE2 Antigens, Secondary Antibodies, Direct One-Step RT-PCR Test Components, Enzymes and others. The full product list is available via https://bit.ly/2DxarJ1.

More Less

About us

Company portrait

Fapon Biotech Inc. was founded in 2001. Guided by the mission of "Enable Disease Identification Earlier, More Accurate, Convenient and Affordable", the company focuses on the future needs and trends of biotechnology developments and provides global diagnostic companies with high-performance IVD reagent raw materials, such as antigens, antibodies, and enzymes, as well as one-stop solutions with instrument and reagent services.

With the profound insight into the healthcare trend that shifts from diseasing treating to disease-preventing, Fapon Biotech had built a comprehensive technology platform. Over 1,300 industrial-grade materials such as antibodies, antigens and enzymes were independently developed and launched, being widely applied in Rapid Test, ELISA, CLIA, CMIA, Biochemistry, Molecular Diagnostics, NGS, etc. One-stop solutions providing open instrument platforms and reagents were also introduced based on the in-depth understanding of industry trends to satisfy customers' needs in different application scenarios.

Fapon Biotech's products and services are highly integrated to promote synergic resources and shared values to the industry. Nowadays, the company has over 1000 partners around the world and is one of the very few Chinese IVD companies that have entered the high-end markets of developed countries in Europe, North America and Asia (Japan). Through continuous innovations in products and services, Fapon Biotech will make the developments of diagnostic technologies benefiting more people and advance the cause of human health.

Company data

Sales volume 200-499 Mio US $
Export content max. 50%
Number of employees 500-999
Foundation 2001
Area of business Imaging and diagnostics / medical equipment and devices